Stem Cell Transplant and Cellular Therapies Symposium 2025: Managing Capacity in the Era of Advanced Therapies
- Continuing Education

Enhance your ability to manage capacity effectively by gaining essential knowledge and strategies to streamline care and improve outcomes for patients undergoing stem cell transplants or CAR T-cell therapies.
- Live Online or In Person
This course is taught in person and online in real time.
Dana-Farber Cancer Institute, Yawkey Center for Cancer Care, Third Floor Conference Center
Continuing Education Credits
Earn up to:
6.00 AMA PRA Category 1 Credit(s) ™
6.00 CNE Nursing (ANCC)
View All
On This Page
Overview
This program addresses the critical need to enhance capacity management among healthcare professionals involved in the care of patients receiving stem cell transplants or CAR T-cell therapies. As these advanced cell therapies become increasingly accessible, healthcare providers face challenges in balancing growing patient volumes with limited resources and infrastructure. This course aims to equip clinicians and community partners with the knowledge and strategies needed to optimize capacity, streamline care delivery, and improve outcomes for patients undergoing these complex treatments.
Learning Objectives
- Summarize the referral process and care coordination between the community oncologist and the transplant team.
- Summarize the latest advancements in stem cell transplant, immune effector cell therapies, and gene therapies.
- Identify common and uncommon post-treatment toxicities post-treatment and differentiate between various common, chronic, and advanced infections post-treatment.
- Learn and create solutions related to capacity management and planning.
- Review other non-infectious concerns that may present during short-term and long-term recovery from treatment.
Developed and Offered By:
Continuing Education courses are developed by faculty from Harvard Medical School's teaching hospitals and accredited by Harvard Medical School. This course is offered by Dana-Farber Cancer Institute.
Schedule
All agenda sessions are in Eastern Time.
Friday, October 17, 2025
Breakfast
8:00-9:00 am
Welcome
Amy Browning Emmert; Kidest Mequanent
9:00-9:10 am
The History of Ambulatory Transplant Program at Dana-Farber
Corey Cutler
9:10-10:00 am
How the Evolution of Immune Effector Cell Therapies Impacts Capacity
Kaitlen Reyes; Clifton Mo; Linda Ramsdell
10:00-11:30 am
Lunch Break
11:30 am-12:30 pm
Infectious Disease Management in Transplant and Cell Therapies
Amy Sherman
12:30-1:15 pm
Managing Capacity in Pediatrics
Leslie Lehmann; Colleen Gerrity
1:15-2:00 pm
Break
2:00-2:15 pm
Cellular Therapies Capacity Management & Planning Panel Discussion
John Reagan; Julie Porter; Amy Browning Emmert; Mark Trusheim
2:15-3:15 pm
Cell Manipulation Core Facilities Program (CMCF) Spotlight – History and Effective Approaches to Managing Capacity as a Manufacturer
Sarah Nikiforow; Jose Cancelas
3:15-4:00 pm
Closing Remarks
Kidest Mequanent
4:00-4:10 pm
Faculty
Corey Cutler, MD, MPH
Course Director
- Director, Adult Stem Cell Transplantation Program
Amy Browning Emmert, MPH
Course Director
- Executive Director, Cell Therapies External Affairs
Kaitlen Reyes, DNP, APRN, FNP-C, AOCNP
Course Director
- Dana-Farber Cancer Institute
Jose Cancelas, MD
Director of Connell and O'Reilly Families Cell Manipulation Core Facility
Colleen Gerrity, MSN, RN, CPHON
Nurse Director of Pediatric Oncology, Dana-Farber Cancer Institute
Caron Jacobson, MD
Medical Director, Immune Effector Cell Therapy Program
Leslie Lehmann, MPH
Clinical Director, Pediatric Stem Cell Transplant Center & Medical Directory for International Hematology Oncology / Bone Marrow Transplant at Boston Children's Hospital
Kidest Mequanent, MHA
Network Manager, Cell Therapies
Clifton Mo, MD
Director of Autologous Stem Cell Transplantation for Multiple Myeloma
Sarah Nikiforow, MD
Technical Director, Immune Effector Cell Therapy Program
Julie Porter, MS
Vice President, Cellular Therapies Operations
Linda Ramsdell, MSN, FNP-BC, OCN
Assistant Program Director of Immune Effector Cellular Therapy
John Reagan, MD
Hematology Oncologist
Amy Sherman, MD
Instructor, Harvard Medical School
Associate Physician, Brigham and Women’s Hospital and Dana-Farber Cancer Institute
Research Associate, Precision Vaccines Program, Boston Children’s Hospital
Mark Trusheim, MS
Founder and President of Co-Bio Consulting, LLC & Strategic Director of NEWDIGS at the MIT Center for Biomedical Innovation
Request Information
Interested in learning more about this program? Sign up for details.
Course Fees
Fee Disclaimer
Dana-Farber Cancer Institute and Mass General Brigham staff are eligible for a registration discount. Contact kidest_mequanent@dfci.harvard.edu.
Role | Course Fee |
---|---|
Physician (MD/DO) | $50.00 |
Nurse (RN/APRN) | $50.00 |
PA | $50.00 |
Psychologist | $50.00 |
Resident/Fellow | $50.00 |
Social Worker | $50.00 |
Allied Health Professional / Other | $50.00 |
Dana-Farber Cancer Institute and Mass General Brigham staff are eligible for a registration discount. Contact kidest_mequanent@dfci.harvard.edu.